Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Why Tilray Is Sinking Today

Insiders were able to sell their shares for the first time on Tuesday. And their selling took a toll on Tilray's share price.

3 Great Stocks Under $10

It's not the low share price that makes these stocks attractive, it's their huge growth prospects.

3 Top Biotech Stocks to Buy in January

Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.

Why Tilray Is Crushing It Today

A big shareholder commits to holding on to its shares of the Canadian marijuana stock, calming investors' concerns about a big sell-off next week.

Why Canopy Growth Jumped Today

Coverage initiation from a leading investment firm stirred investors' enthusiasm for the Canadian marijuana stock.

Why Tilray Surged Today

An influential analyst's Increased optimism boosted the Canadian marijuana stock.